These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 27769048)
1. FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells. Lin B; Chen T; Zhang Q; Lu X; Zheng Z; Ding J; Liu J; Yang Z; Geng L; Wu L; Zhou L; Zheng S Oncotarget; 2016 Nov; 7(47):77495-77507. PubMed ID: 27769048 [TBL] [Abstract][Full Text] [Related]
2. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway. Wang X; Wang R; Bai S; Xiong S; Li Y; Liu M; Zhao Z; Wang Y; Zhao Y; Chen W; Billiar TR; Cheng B J Exp Clin Cancer Res; 2019 Dec; 38(1):505. PubMed ID: 31888685 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Liao W; Liu W; Liu X; Yuan Q; Ou Y; Qi Y; Huang W; Wang Y; Huang J Oncotarget; 2015 Sep; 6(27):24132-47. PubMed ID: 26125229 [TBL] [Abstract][Full Text] [Related]
4. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692 [TBL] [Abstract][Full Text] [Related]
5. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma. Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681 [TBL] [Abstract][Full Text] [Related]
7. FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma. Wang D; Han S; Peng R; Wang X; Yang XX; Yang RJ; Jiao CY; Ding D; Ji GW; Li XC Biochem Biophys Res Commun; 2015 Mar; 458(2):313-20. PubMed ID: 25646692 [TBL] [Abstract][Full Text] [Related]
8. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits. Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214 [TBL] [Abstract][Full Text] [Related]
10. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition. Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927 [TBL] [Abstract][Full Text] [Related]
11. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma. Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482 [TBL] [Abstract][Full Text] [Related]
12. Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met. Chen JJ; Sun X; Mao QQ; Jiang XY; Zhao XG; Xu WJ; Zhong L Kaohsiung J Med Sci; 2020 Mar; 36(3):196-205. PubMed ID: 31749294 [TBL] [Abstract][Full Text] [Related]
13. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. Huang WC; Tung SL; Chen YL; Chen PM; Chu PY BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298 [TBL] [Abstract][Full Text] [Related]
14. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α. Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451 [TBL] [Abstract][Full Text] [Related]
15. Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. Ou H; Chen Z; Xiang L; Fang Y; Xu Y; Liu Q; Hu Z; Li X; Huang Y; Yang D Cancer Sci; 2019 Apr; 110(4):1169-1182. PubMed ID: 30677195 [TBL] [Abstract][Full Text] [Related]
16. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis. Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348 [TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Wang D; Fu L; Sun H; Guo L; DuBois RN Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008 [TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma. Sakabe T; Azumi J; Umekita Y; Toriguchi K; Hatano E; Hirooka Y; Shiota G Liver Int; 2017 Feb; 37(2):271-279. PubMed ID: 27473646 [TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of CD44 and TGF-β1 through AKT/GSK-3β/β-catenin signaling during epithelial-mesenchymal transition in liver cancer cells. Park NR; Cha JH; Jang JW; Bae SH; Jang B; Kim JH; Hur W; Choi JY; Yoon SK Biochem Biophys Res Commun; 2016 Sep; 477(4):568-574. PubMed ID: 27320862 [TBL] [Abstract][Full Text] [Related]
20. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression. Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]